Literature DB >> 12385773

Expression and functional analysis of rat P23, a gut hormone-inducible isoform of trypsin, reveals its resistance to proteinaceous trypsin inhibitors.

Shin-Ichi Fukuoka1, Cornelio M Nyaruhucha.   

Abstract

Rat P23 is an isoform of trypsin (ogens) synthesized by rat acinar cells. Expression of P23 is stimulated strongly by caerulein, an analogue of cholecystokinin (CCK). However, the physiological relevance of rat P23 in healthy and pathological conditions such as caerulein-induced pancreatitis is largely unknown. Using recombinant P23 trypsinogen and reconstitution analysis of zymogen autoactivation, unique inhibitor-resistance characteristics of P23 were elucidated. P23 cDNA was expressed in Escherichia coli periplasm, yielding recombinant P23 trypsinogen. Autoactivation of zymogen granule contents from caerulein-induced rat pancreas was also studied. Activation kinetics of P23 by enterokinase was similar to those of rat anionic trypsinogen, which is a major isoform of trypsinogen. Interestingly, rat pancreatic secretory trypsin inhibitor (PSTI), which protects against deleterious activation of trypsinogens in zymogen granules, failed to inhibit P23 trypsin even with four-fold molar excess, at which concentration it effectively inhibited rat anionic trypsin to almost 100%. P23 trypsin also showed marked resistance to proteinaceous trypsin inhibitors such as soybean trypsin inhibitor and aprotinin. P23 trypsin activated by enterokinase dramatically accelerated the cascade of autoactivation of anionic trypsinogen even in the presence of PSTI. Taken together with a previous observation that P23 is specifically upregulated 14-fold by 24-h caerulein infusion, these results suggest that elevated levels of P23 should be taken into consideration in the mechanism of trypsinogens within the pancreas in pathological conditions.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12385773     DOI: 10.1016/s0925-4439(02)00153-9

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  6 in total

1.  Mesotrypsin Has Evolved Four Unique Residues to Cleave Trypsin Inhibitors as Substrates.

Authors:  Alexandre P Alloy; Olumide Kayode; Ruiying Wang; Alexandra Hockla; Alexei S Soares; Evette S Radisky
Journal:  J Biol Chem       Date:  2015-07-14       Impact factor: 5.157

Review 2.  Human mesotrypsin defies natural trypsin inhibitors: from passive resistance to active destruction.

Authors:  Miklós Sahin-Tóth
Journal:  Protein Pept Lett       Date:  2005-07       Impact factor: 1.890

3.  Serine proteases mediate inflammatory pain in acute pancreatitis.

Authors:  Eugene P Ceppa; Victoria Lyo; Eileen F Grady; Wolfgang Knecht; Sarah Grahn; Anders Peterson; Nigel W Bunnett; Kimberly S Kirkwood; Fiore Cattaruzza
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2011-03-24       Impact factor: 4.052

4.  Protease-activated receptor 2, dipeptidyl peptidase I, and proteases mediate Clostridium difficile toxin A enteritis.

Authors:  Graeme S Cottrell; Silvia Amadesi; Stella Pikios; Eric Camerer; J Adam Willardsen; Brett R Murphy; George H Caughey; Paul J Wolters; Shaun R Coughlin; Anders Peterson; Wolfgang Knecht; Charalabos Pothoulakis; Nigel W Bunnett; Eileen F Grady
Journal:  Gastroenterology       Date:  2007-04-13       Impact factor: 22.682

5.  Human mesotrypsin is a unique digestive protease specialized for the degradation of trypsin inhibitors.

Authors:  Richárd Szmola; Zoltán Kukor; Miklos Sahin-Tóth
Journal:  J Biol Chem       Date:  2003-09-24       Impact factor: 5.157

6.  Ginsenoside Rh3 Inhibits Lung Cancer Metastasis by Targeting Extracellular Signal-Regulated Kinase: A Network Pharmacology Study.

Authors:  Xiaodan Xue; Yannan Liu; Linlin Qu; Cuiying Fan; Xiaoxuan Ma; Pingkai Ouyang; Daidi Fan
Journal:  Pharmaceuticals (Basel)       Date:  2022-06-17
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.